0
0
In a study published today, AGES determined the effectiveness of COVID vaccines licensed in Austria: The mRNA vaccines showed the best protection against infection across all age groups, even against the delta variant.
In the over-60s, AstraZeneca’s efficacy was nearly equal, beaten by J&J. “This current study shows once again that vaccination works,” emphasized Health Minister Wolfgang Mückstein (Greens).
In Austria, the mRNA vaccines (from BioNTech and Pfizer as well as Moderna) as well as AstraZeneca and Johnson & Johnson have been used so far. For the entire study period (Weeks 5 to 35), the highest efficacy against symptomatic infection was found with the mRNA vaccines. This was around 95 percent in 12- to 17-year-olds and around 85 percent in each of the older age groups.
Protection increases with age at J&J and AstraZeneca
For Johnson & Johnson, effectiveness increased with age – rising from just under 38 percent to nearly 65 percent among those over 60. AstraZeneca offered the most protection to the oldest age group at over 80 percent, and it was still 61.24 percent among 18- to 39-year-olds.
The Johnson & Johnson vaccine was approved for a single vaccination. Mückstein: “The new results of the AGES study confirm the recommendation of the National Vaccination Panel: those persons who received a vaccination from Johnson & Johnson need a second vaccination dose to continue to be adequately protected.”
— source: ORF.at/agencies/picture: pixabay.com
This post has already been read 856 times!
